

# Mariano Provencio Pulla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629678/publications.pdf>

Version: 2024-02-01

246  
papers

18,387  
citations

30070  
54  
h-index

13771  
129  
g-index

256  
all docs

256  
docs citations

256  
times ranked

19331  
citing authors

#	ARTICLE	IF	CITATIONS
1	Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study. Archivos De Bronconeumologia, 2022, 58, 542-546.	0.8	10
2	Fruits and Vegetables and Lung Cancer Risk in Never Smokers. A Multicentric and Pooled Case-Control Study. Nutrition and Cancer, 2022, 74, 613-621.	2.0	2
3	Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 188-200.	2.8	6
4	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	7.0	9
5	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	27.0	871
6	Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. Cancers, 2022, 14, 2158.	3.7	3
7	Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy. Oncogenesis, 2022, 11, 24.	4.9	7
8	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 711-728.	3.8	12
9	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Journal of Clinical Oncology, 2022, 40, 2924-2933.	1.6	127
10	Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Molecular Oncology, 2021, 15, 43-56.	4.6	18
11	Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group. Hematological Oncology, 2021, 39, 506-512.	1.7	2
12	Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2021, 60, 81-88.	1.4	37
13	Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer, 2021, 21, 230.	2.6	9
14	ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1221-1229.	2.3	7
15	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer, 2021, 153, 25-34.	2.0	17
16	The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. Biomedicines, 2021, 9, 361.	3.2	7
17	Residential radon and lung cancer characteristics at diagnosis. International Journal of Radiation Biology, 2021, 97, 997-1002.	1.8	4
18	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2193-2204.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptorâ€“positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. European Journal of Cancer, 2021, 149, 61-72.	2.8	21
20	Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. Translational Lung Cancer Research, 2021, 10, 2588-2602.	2.8	5
21	NGSâ€“based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Molecular Oncology, 2021, 15, 2363-2376.	4.6	16
22	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. , 2021, 9, e002323.		26
23	Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. Translational Lung Cancer Research, 2021, 10, 2715-2732.	2.8	11
24	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 2021, 11, e491.	4.0	26
25	Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIa) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Research, 2021, 81, CT003-CT003.	0.9	74
26	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Management, 2021, 10, LMT51.	1.5	10
27	Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer, 2021, 157, 109-115.	2.0	24
28	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Future Oncology, 2021, 17, 4011-4025.	2.4	10
29	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer, 2021, 21, 977.	2.6	5
30	Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2021, 22, 86.	3.0	10
31	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clinical Cancer Research, 2021, 27, 5878-5890.	7.0	30
32	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
33	R-Score: A New Parameter to Assess the Quality of Variantsâ€™™ Calls Assessed by NGS Using Liquid Biopsies. Biology, 2021, 10, 954.	2.8	1
34	Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. Cancers, 2021, 13, 4622.	3.7	6
35	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	2.8	12
36	Are there differences by sex in lung cancer characteristics at diagnosis? â€“a nationwide study. Translational Lung Cancer Research, 2021, 10, 3902-3911.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Next-generation sequencing for tumor mutation quantification using liquid biopsies. Clinical Chemistry and Laboratory Medicine, 2020, 58, 306-313.	2.3	10
38	ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. Translational Lung Cancer Research, 2020, 9, 532-540.	2.8	17
39	Lung cancer symptoms at diagnosis: results of a nationwide registry study. ESMO Open, 2020, 5, e001021.	4.5	15
40	Lung cancer risk and residential radon exposure: A pooling of case-control studies in northwestern Spain. Environmental Research, 2020, 189, 109968.	7.5	38
41	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1413-1422.	10.7	475
42	A Data-Driven Approach for Analyzing Healthcare Services Extracted from Clinical Records. , 2020, , .		2
43	Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report. Translational Lung Cancer Research, 2020, 9, 366-372.	2.8	19
44	Reconstructing the patient's natural history from electronic health records. Artificial Intelligence in Medicine, 2020, 105, 101860.	6.5	14
45	Clinical utility of liquid biopsy for the diagnosis and monitoring of <i>EML4-ALK</i> NSCLC patients. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
46	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205
47	Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiology, 2020, 67, 101737.	1.9	15
48	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2020, 9, 2656-2673.	2.8	16
49	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2696-2715.	2.8	43
50	Utilidad cl�nica de la biopsia l�quida para el diagn�stico y seguimiento de los pacientes con CPNM y <i>EML4-ALK</i>. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
51	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Revista Espanola De Patologia, 2020, 53, 140-148.	0.2	0
52	ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	2.4	42
53	Residential radon, genetic polymorphisms in DNA damage and repair-related. Lung Cancer, 2019, 135, 10-15.	2.0	21
54	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.	2.8	38

#	ARTICLE	IF	CITATIONS
55	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	4.5	38
56	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer, 2019, 134, 72-78.	2.0	24
57	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 1266-1276.	1.1	78
58	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European Journal of Cancer, 2019, 116, 137-147.	2.8	167
59	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology, 2019, 37, 1997-2007.	1.6	170
60	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
61	Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1 $\alpha$ in NSCLC which can be overcome by OXPHOS inhibition. Free Radical Biology and Medicine, 2019, 135, 167-181.	2.9	108
62	Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain. Environmental Research, 2019, 172, 713-718.	7.5	60
63	Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. Hematological Oncology, 2019, 37, 143-150.	1.7	9
64	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. Blood Cancer Journal, 2019, 9, 34.	6.2	23
65	How we treat patients with lung cancer during the SARS-CoV-2 pandemic. ESMO Open, 2019, 4, e000785.	4.5	2
66	Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. Leukemia and Lymphoma, 2019, 60, 856-859.	1.3	4
67	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 304-310.	1.1	10
68	Clinical utility of plasma-based digital next-generation sequencing in patients with advanced-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Annals of Oncology, 2019, 30, 290-296.	1.2	55
69	Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- $\beta$ 2 signaling. Free Radical Biology and Medicine, 2019, 130, 163-173.	2.9	91
70	Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies. Pathology Research and Practice, 2019, 215, 392-394.	2.3	11
71	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clinical and Translational Oncology, 2019, 21, 3-17.	2.4	110
72	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Lung Cancer, 2019, 135, 161-168.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	1.3	6
74	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	1.3	0
75	A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. <i>Clinical and Translational Oncology</i> , 2019, 21, 489-498.	2.4	65
76	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.	1.5	6
77	Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies. <i>European Journal of Public Health</i> , 2018, 28, 521-527.	0.3	13
78	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	1.2	106
79	Características al diagnóstico y supervivencia de estadios I y II de cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2018, 54, 420-426.	0.8	4
80	Lung cancer in lung transplantation: incidence and outcome. <i>Postgraduate Medical Journal</i> , 2018, 94, 15-19.	1.8	22
81	Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 488-494.	1.8	30
82	Profiling Lung Cancer Patients Using Electronic Health Records. <i>Journal of Medical Systems</i> , 2018, 42, 126.	3.6	17
83	An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement. <i>PLoS ONE</i> , 2018, 13, e0193233.	2.5	9
84	Hyperprogression as a distinct outcome after immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 16-21.	7.7	89
85	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	2.6	9
86	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2018, 24, 5543-5551.	7.0	18
87	Long-term follow up of Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 11638-11645.	1.8	7
88	Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib. <i>Annals of Translational Medicine</i> , 2018, 6, S31-S31.	1.7	0
89	Association of DDX58 polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 438-444.	1.3	2
90	Follicular lymphomas and their transformation: Past and current research. <i>Expert Review of Hematology</i> , 2017, 10, 515-524.	2.2	8

#	ARTICLE	IF	CITATIONS
91	Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer. Oncology Letters, 2017, 13, 1647-1654.	1.8	5
92	Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. Cancer, 2017, 123, 3709-3716.	4.1	23
93	Exercise and the Hallmarks of Cancer. Trends in Cancer, 2017, 3, 423-441.	7.4	124
94	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer, 2017, 108, 154-160.	2.0	18
95	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. Cancer Investigation, 2017, 35, 358-365.	1.3	9
96	Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study. Cancer Letters, 2017, 411, 130-135.	7.2	9
97	El tumor del estroma gastrointestinal y la aparici3n de segundos tumores: revisi3n de la bibliografAa. Medicina ClAnica, 2017, 149, 345-350.	0.6	7
98	C4ncer de pulm3n microc4tico. MetodologAa y resultados preliminares del estudio SMALL CELL. Archivos De Bronconeumologia, 2017, 53, 675-681.	0.8	5
99	Lung cancer as a cardiotoxic state: a review. Medical Oncology, 2017, 34, 159.	2.5	12
100	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	6.3	128
101	PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy. Scientific Reports, 2017, 7, 16661.	3.3	21
102	Small Cell Lung Cancer. Methodology and Preliminary Results of the SMALL CELL Study. Archivos De Bronconeumologia, 2017, 53, 675-681.	0.8	0
103	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. Clinical Lung Cancer, 2017, 18, 178-188.e4.	2.6	5
104	Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 186-191.	0.4	29
105	Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK). ADMET and DMPK, 2017, 5, 1.	2.1	0
106	Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 102888-102897.	1.8	22
107	Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2843-2846.	1.4	0
108	Copanlisib in patients with relapsed or refractory follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7535-7535.	1.6	5



#	ARTICLE	IF	CITATIONS
109	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. PLoS ONE, 2017, 12, e0177204.	2.5	18
110	mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. Oncotarget, 2017, 8, 50949-50957.	1.8	31
111	Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. Oncotarget, 2017, 8, 59408-59416.	1.8	12
112	Dynamic circulating tumor DNA quantification for the individualization of non-small-cell lung cancer patients treatment. Oncotarget, 2017, 8, 60291-60298.	1.8	22
113	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget, 2017, 8, 111386-111395.	1.8	33
114	Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Translational Lung Cancer Research, 2016, 5, 455-465.	2.8	79
115	CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3 $\beta$ signaling pathway. Oncotarget, 2016, 7, 68781-68791.	1.8	51
116	Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Translational Lung Cancer Research, 2016, 5, 665-672.	2.8	114
117	Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. European Respiratory Journal, 2016, 48, 1462-1470.	6.7	32
118	Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. Molecular and Clinical Oncology, 2016, 4, 93-99.	1.0	2
119	Small cell lung cancer in never-smokers. European Respiratory Journal, 2016, 47, 947-953.	6.7	32
120	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. Anticancer Research, 2016, 36, 6647-6654.	1.1	9
121	Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk. Journal of Thoracic Oncology, 2015, 10, 1279-1284.	1.1	27
122	Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience, 2015, 2, 131-141.	2.2	57
123	HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01:02. PLoS ONE, 2015, 10, e0135512.	2.5	9
124	High-dose Chemotherapy Followed by Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Follicular Non-Hodgkin's Lymphoma in the Rituximab Era. Tumori, 2015, 101, 2-7.	1.1	1
125	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treatment Reviews, 2015, 41, 680-689.	7.7	43
126	Sentinel lymph node biopsy in breast cancer: the role of micrometastasis. Medical Oncology, 2015, 32, 450.	2.5	1



#	ARTICLE	IF	CITATIONS
127	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1286-1294.	1.3	10
128	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015, 54, 933-938.	1.8	11
129	Insight in paranoia: The role of experiential avoidance and internalized stigma. <i>Schizophrenia Research</i> , 2015, 164, 214-220.	2.0	27
130	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <i>Cancer Epidemiology</i> , 2015, 39, 291-297.	1.9	39
131	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	10.7	124
132	Residential radon and lung cancer characteristics in never smokers. <i>International Journal of Radiation Biology</i> , 2015, 91, 605-610.	1.8	23
133	Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1686-1690.	1.3	5
134	Exosomes enriched in stemness/metastatic-related mRNAs promote oncogenic potential in breast cancer. <i>Oncotarget</i> , 2015, 6, 40575-40587.	1.8	70
135	Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e98169.	2.5	31
136	Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 51-55.	1.3	21
137	High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1413-1416.	1.3	5
138	Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 78-90.	2.5	6
139	Different exosome cargo from plasma/bronchoalveolar lavage in non-small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 713-724.	2.8	121
140	New drugs and targeted treatments in Hodgkin's lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 457-464.	7.7	10
141	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	3.5	2
142	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	1.4	193
143	Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 89-94.	2.8	16
144	Cancer-associated fibroblast and $\alpha$ 2 macrophage markers together predict outcome in colorectal cancer patients. <i>Cancer Science</i> , 2013, 104, 437-444.	3.9	235

#	ARTICLE	IF	CITATIONS
145	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Medical Oncology, 2013, 30, 572.	2.5	21
146	False-positive interpretations in respiratory cytopathology. Clinical Rheumatology, 2013, 32, 15-17.	2.2	1
147	Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications. Clinical and Developmental Immunology, 2012, 2012, 1-24.	3.3	28
148	Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab. Case Reports in Oncology, 2012, 5, 676-681.	0.7	9
149	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	10.7	4,943
150	Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews, 2012, 38, 36-53.	7.7	57
151	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer, 2012, 76, 354-361.	2.0	29
152	Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer. Journal of Gastrointestinal Cancer, 2012, 43, 553-561.	1.3	11
153	Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?. Clinical and Translational Oncology, 2012, 14, 386-390.	2.4	4
154	Breast cancer occurred after Hodgkin's disease: Clinico-pathological features, treatments and outcome: Analysis of 214 cases. Critical Reviews in Oncology/Hematology, 2012, 81, 29-37.	4.4	29
155	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	2.6	36
156	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leukemia and Lymphoma, 2011, 52, 1-14.	1.3	16
157	Predictors of subjective well-being in patients with paranoid symptoms: Is insight necessarily advantageous?. Psychiatry Research, 2011, 189, 190-194.	3.3	26
158	Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin lymphoma. Histopathology, 2011, 59, 349-352.	2.9	5
159	Activity of trabectedin in desmoplastic small round cell tumor. Medical Oncology, 2011, 28, 644-646.	2.5	21
160	PET-CT in the staging and treatment of non-small-cell lung cancer. Clinical and Translational Oncology, 2011, 13, 368-377.	2.4	16
161	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical and Translational Oncology, 2011, 13, 411-418.	2.4	0
162	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. Clinical Cancer Research, 2011, 17, 1160-1168.	7.0	292

#	ARTICLE	IF	CITATIONS
163	Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications. <i>Leukemia and Lymphoma</i> , 2011, 52, 2162-2168.	1.3	14
164	Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. <i>European Respiratory Journal</i> , 2011, 37, 617-623.	6.7	260
165	Implicit and explicit self-esteem discrepancies in paranoia and depression.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 691-699.	1.9	45
166	Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 179-187.	1.3	13
167	Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , 2011, 3, 197-204.	1.4	44
168	New molecular targeted therapies for advanced non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2011, 3, 30-56.	1.4	29
169	Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 384-386.	2.4	1
170	Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. <i>Clinical and Translational Oncology</i> , 2010, 12, 701-703.	2.4	8
171	SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 753-759.	2.4	2
172	SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 765-769.	2.4	1
173	New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 91-97.	2.6	56
174	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	2.2	49
175	Old and New Insights in the Treatment of Thyroid Carcinoma. <i>Journal of Thyroid Research</i> , 2010, 2010, 1-16.	1.3	9
176	Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-17.	3.0	13
177	Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 2021-2030.	1.3	8
178	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	2.0	8
179	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.	2.0	13
180	Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-6.	1.3	15

#	ARTICLE	IF	CITATIONS
181	A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1642-1646.	1.3	8
182	Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients. <i>Clinical Cancer Research</i> , 2009, 15, 4823-4828.	7.0	12
183	Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. <i>Clinical and Translational Oncology</i> , 2009, 11, 35-40.	2.4	9
184	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.	2.4	14
185	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 428-436.	2.4	4
186	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	2.4	3
187	Lung cancer and treatment in elderly patients: The Achilles Study. <i>Lung Cancer</i> , 2009, 66, 103-106.	2.0	18
188	Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?. <i>Clinical Lung Cancer</i> , 2009, 10, 295-300.	2.6	23
189	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	27.0	2,213
190	Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. <i>PLoS ONE</i> , 2009, 4, e5133.	2.5	153
191	Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. <i>PLoS ONE</i> , 2009, 4, e8173.	2.5	26
192	Circulating tumor cells in breast cancer: methodology and clinical repercussions. <i>Clinical and Translational Oncology</i> , 2008, 10, 399-406.	2.4	8
193	Hodgkin's disease and intercurrent processes that may simulate a relapse. <i>Clinical and Translational Oncology</i> , 2008, 10, 439-441.	2.4	1
194	R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. <i>Hematological Oncology</i> , 2008, 26, 27-32.	1.7	15
195	A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. <i>Clinical Breast Cancer</i> , 2008, 8, 149-154.	2.4	34
196	Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5300-5305.	7.0	11
197	Flumazenil in the Treatment of Dizziness and Vegetative Symptoms after Intravenous Infusion of Paclitaxel. <i>Onkologie</i> , 2008, 31, 203-203.	0.8	1
198	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2008, 14, 4794-4799.	7.0	99

#	ARTICLE	IF	CITATIONS
199	Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of an International Phase II Trial. Journal of Thoracic Oncology, 2008, 3, 994-1002.	1.1	48
200	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 2747-2754.	1.6	445
201	Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology, 2007, 25, 4736-4742.	1.6	104
202	P3-080: Erlotinib as single agent in men with advanced or metastatic NSCLC: A retrospective analysis. Journal of Thoracic Oncology, 2007, 2, S712-S713.	1.1	3
203	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood, 2006, 108, 662-668.	1.4	131
204	Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes and Cancer, 2006, 45, 692-701.	2.8	41
205	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Annals of Oncology, 2006, 17, 467-472.	1.2	117
206	Implication of Polycomb Members Bmi-1, Mel-18, and Hpc-2 in the Regulation of p16INK4a, p14ARF, h-TERT, and c-Myc Expression in Primary Breast Carcinomas. Clinical Cancer Research, 2006, 12, 6929-6936.	7.0	76
207	Rapid-infusion rituximab in lymphoma treatment. Annals of Oncology, 2006, 17, 1027-1028.	1.2	25
208	Association Between Hepatitis C Virus and Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2006, 24, 3513-3513.	1.6	2
209	Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential. Clinical Cancer Research, 2006, 12, 2095-2100.	7.0	35
210	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2004, 10, 1318-1325.	7.0	345
211	Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 554, 215-221.	1.0	13
212	Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomas. Genes Chromosomes and Cancer, 2004, 39, 257-262.	2.8	7
213	Promoter methylation of the <i>PTEN</i> gene is a common molecular change in breast cancer. Genes Chromosomes and Cancer, 2004, 41, 117-124.	2.8	196
214	Prognostic Factors in Hodgkin's Disease. Leukemia and Lymphoma, 2004, 45, 1133-1139.	1.3	12
215	Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. Annals of Surgical Oncology, 2003, 10, 150-154.	1.5	129
216	Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Seminars in Oncology, 2003, 30, 19-25.	2.2	34

#	ARTICLE	IF	CITATIONS
217	Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. <i>Journal of Pathology</i> , 2003, 199, 289-297.	4.5	100
218	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	1.6	420
219	Intratumoral Heterogeneity in Microsatellite Alterations in BRCA1 and PTEN Regions in Sporadic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 876-881.	1.5	13
220	The Management of Stage III Supradiaphragmatic Hodgkin's Disease with Chemotherapy Alone. <i>Leukemia and Lymphoma</i> , 2003, 44, 263-268.	1.3	4
221	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	1.6	177
222	Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. <i>Gut</i> , 2002, 50, 530-534.	12.1	124
223	Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. <i>Annals of Surgical Oncology</i> , 2002, 9, 71-76.	1.5	61
224	p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. <i>Clinical Cancer Research</i> , 2002, 8, 980-5.	7.0	84
225	Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. <i>Clinical Cancer Research</i> , 2002, 8, 3761-6.	7.0	97
226	Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. <i>Radiotherapy and Oncology</i> , 2001, 59, 247-255.	0.6	92
227	Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 183-190.	2.5	52
228	Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. <i>Oncogene</i> , 2001, 20, 4586-4590.	5.9	46
229	Hodgkin's Disease: Unsuspected Minimal Activity in Patients that Die from Causes Other than Tumoral Progression. <i>Leukemia and Lymphoma</i> , 2001, 42, 661-664.	1.3	4
230	Breast cancer: contribution of molecular biology to the management of the disease. , 2001, 3, 130-136.		2
231	Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance. <i>Annals of Oncology</i> , 2000, 11, 1097-1104.	1.2	81
232	DNA damage after chemotherapy correlates with tumor response and survival in small cell lung cancer patients. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000, 456, 65-71.	1.0	5
233	Clinicopathological characteristics of breast carcinomas with allelic loss in the p73. <i>Breast Cancer Research and Treatment</i> , 2000, 63, 17-22.	2.5	8
234	Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. <i>British Journal of Cancer</i> , 2000, 82, 1183-1185.	6.4	40

#	ARTICLE	IF	CITATIONS
235	Metastatic Renal Cell Carcinoma to the Head and Neck Area. Tumori, 2000, 86, 88-90.	1.1	17
236	Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. British Journal of Cancer, 1999, 80, 1262-1264.	6.4	116
237	Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. British Journal of Cancer, 1999, 81, 503-509.	6.4	70
238	Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Research and Treatment, 1999, 53, 9-17.	2.5	31
239	Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Research and Treatment, 1999, 57, 237-243.	2.5	104
240	Low Incidence of Germline BRCA2 Gene Mutations among Spanish Breast Cancer Patients. Oncology, 1999, 57, 173-174.	1.9	4
241	Loss of Heterozygosity in the Region Including the BRCA1 Gene on 17q in Colon Cancer. Cancer Genetics and Cytogenetics, 1998, 104, 119-123.	1.0	36
242	BRCA1 Mutations in Patients with Familial Risk of Breast Cancer. Acta Oncol3gica, 1998, 37, 299-300.	1.8	0
243	Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.. Journal of Clinical Oncology, 1998, 16, 115-120.	1.6	34
244	Breast Angiosarcoma After Radiation Therapy. Acta Oncol3gica, 1995, 34, 969-969.	1.8	23
245	Malignant Fibrous Histiocytoma of the Spleen and Chronic Myelogenous Leukemia. Oncology, 1994, 51, 465-466.	1.9	13
246	Pneumomediastinum after belching. Lancet, The, 1990, 336, 1390.	13.7	3